^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SOR C13

    i
    Other names: SOR C13, SOR-C13, SORC13
    Associations

    News

    Trials
    Company:
    Soricimed
    Drug class:
    TRPV6 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=11, Completed, M.D. Anderson Cancer Center | Recruiting --> Completed | N=36 --> 11
    Trial completion • Enrollment change • Metastases
    |
    TRPV6 (Transient Receptor Potential Cation Channel Subfamily V Member 6)
    |
    TRPV6 overexpression
    |
    SOR C13
    2years
    SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=36, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Aug 2022 --> Aug 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    TRPV6 (Transient Receptor Potential Cation Channel Subfamily V Member 6)
    |
    SOR C13